CJC-1295 DAC
Healthy adults · SubQ phase 1 dose-finding · Teichman 2006
CJC-1295 DAC is a long-acting GHRH analogue. This card shows selected single-dose cohorts in healthy adults. Healthy adults · SubQ phase 1 dose-finding · Teichman 2006.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| STUDY CONTEXT | Dose | Frequency | Context |
|---|---|---|---|
| Selected cohort | 30 mcg/kg | Single dose | Source |
| Selected cohort | 60 mcg/kg | Single dose | Source |
These two selected single-dose cohorts are not a weekly maintenance prescription. They do not apply to CJC-1295 without DAC, and hormone increases do not establish a clinical benefit.
Source context
The placebo-controlled phase 1 work measured growth hormone and IGF-I responses. The long-acting material contains the drug affinity complex; the paper also reports other dose and repeat-exposure cohorts.
Reading the dose correctly
These two selected single-dose cohorts are not a weekly maintenance prescription. They do not apply to CJC-1295 without DAC, and hormone increases do not establish a clinical benefit.
Download the chart
Further reading
CJC-1295 DAC monograph on myPeptides
References
Does the reference apply to other formulations?
Only the product, preparation and route named here are covered. A shared substance name does not establish an equivalent amount for another formulation.
Where can I read the wider evidence?
The linked myPeptides CJC-1295 DAC monograph covers the mechanism, human and preclinical evidence, and important distinctions between related substances.